Principal Financial Group Inc Verve Therapeutics, Inc. Transaction History

Principal Financial Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 29, 2024	BUY	$10.81 - $17.96 $3,080 - $5,118	285 Added 1.85%	15,649 $207,000
Q4 2023 Feb 07, 2024	SELL	$8.84 - $18.7 $13,109 - $27,732	-1,483 Reduced 8.8%	15,364 $214,000
Q3 2023 Nov 02, 2023	BUY	$11.42 - $20.82 $29,303 - $53,424	2,566 Added 17.97%	16,847 $223,000
Q2 2023 Aug 07, 2023	BUY	$13.34 - $19.9 $6,790 - $10,129	509 Added 3.7%	14,281 $267,000
Q1 2023 May 09, 2023	BUY	$14.3 - $24.01 $19,505 - $32,749	1,364 Added 10.99%	13,772 $198,000
Q4 2022 Feb 09, 2023	BUY	$17.85 - $40.7 $33,611 - $76,638	1,883 Added 17.89%	12,408 $240,000
Q3 2022 Nov 09, 2022	BUY	$15.63 - $41.49 $164,505 - $436,682	10,525 New	10,525 $361,000
Q1 2022 May 09, 2022	SELL	$20.92 - $39.36 $120,080 - $225,926	-5,740 Closed	0 $0
Q4 2021 Feb 09, 2022	BUY	$31.94 - $54.82 $183,335 - $314,666	5,740 New	5,740 $212,000

173

74.7M

115K

144K

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $299M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.